Do you want to read an article? Please log in or register.
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials
COPD
RECOMMENDED
Related content
AsthmaCOPD
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
Lancet Respir Med.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M
doi: 10.1016/
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial
Am J Respir Crit Care Med.
Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI.
doi: 10.1164/
COMMENTED
COPD
Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS
Ann Am Thorac Soc.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, Barr RG, Krishnan JA, Lazarus SC, Cooper CB, Paine R 3rd, Peters SP, Hansel NN, Martinez FJ, Drummond MB, Current and former investigators of the SPIROMICS sites and reading centers
doi: 10.1513/AnnalsATS.201804-283OC.
COMMENTED
COPD
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Cochrane Database Syst Rev.
Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA
doi: 10.1002/14651858.
RECOMMENDED
COPD
Chronic Obstructive Pulmonary Disease in the Intensive Care Unit: Antibiotic Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Semin Respir Crit Care Med.
Gupta N, Haley R, Gupta A, Sethi S
doi: 10.1055/s-0040-1708837.
COPD
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials
Respir Med.
Ferguson GT, Buhl R, Bothner U, Hoz A, Voß F, Anzueto A, Calverley PMA
doi: 10.1016/j.rmed.2018.08.012.
COPDPneumonia
Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention
Eur J Cardiothorac Surg.
Andell P, Sjögren J, Batra G, Szummer K, Koul S
doi: 10.1093/ejcts/ezx219.
RECOMMENDED
COPDPneumonia
Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med.
Alispahic IA, Sørensen R, Eklöf J, Sivapalan P, Løkke A, Seersholm N, Vestergaard JH, Jensen JS
doi: 10.3390/jcm9051442.
RECOMMENDED
COPD
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
Lancet Respir Med.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D
doi: 10.1016/S2213-2600(19)30190-0.